Together, we can end blood culture contamination.
Blood cultures remain the gold standard for diagnosing sepsis - the leading cause of death and readmission in US hospitals. Even with best practices, between 35-50% of blood culture tests are contaminated, resulting in false-positive diagnoses that place over one million lives at risk each year.
Current best practices are susceptible to:
Risk of contamination during assembly and preparation of supplies, and skin prep
You can disinfect but not sterilize the skin; up to 20% of skin flora remains viable in the keratin layer of the skin even after skin prep
Skin plugs, when present, will always enter the culture specimen bottle and commonly will contain microorganisms
Fortunately, we’ve found a solution...
The only vein-to-bottle closed blood culture collection system that is clinically proven to virtually eliminate the preventable error of blood culture contamination and false-positive results for sepsis.
Preassembled & sterile:
eliminates touch-point contamination
Initial specimen diversion mechanism:
ensures effective diversion every time
Diversion specimen isolation chamber:
ensures contaminants are isolated from the blood culture specimen
User-controlled negative-pressure diversion:
enables necessary adjustments for “hard stick” patients with low venous pressure
Independent second sterile blood flow path:
allows only pure venous blood, without skin contaminants, to flow into culture bottles
Using Steripath, our customers have successfully:
Improved patient safety, care and experience
By reducing risks of developing antibiotic-resistant infections due to unnecessary use of antibiotics and decreases the risk of hospital-acquired conditions associated with unnecessary extended length of stay.
Driven antimicrobial stewardship compliance
Supporting compliance with the federally mandated requirements to implement an effective antimicrobial stewardship program that reduces unnecessary and inappropriate use of antibiotics.
Reduced hospital and system-wide costs
By decreasing avoidable costs for non-reimbursable tests, treatments of complications due to antibiotic-resistant infections and other complications, and unnecessary extended length of stay due to antibiotic-resistant infections and conditions.
Maximized hospital reimbursement and incentives
Impacting key CMS quality outcome metrics - such as complications, readmissions, and patient experience scores - dictating the hospital’s CMS reimbursement and Value-Based Purchasing incentive dollars.
Steripath is available in multiple configurations
Users can collect blood cultures through peripheral sticks and initial IV starts. It is also compatible with standard blood collection tubes and culture bottles made by BD, bioMerieux and certain Thermo Scientific products.
21-gauge push button safety needle
23-gauge push button safety needle
Luer IV extension set
Available Transfer Adapters
Steripath has been clinically proven to
sustain a blood culture contamination rate of 0.2%
and a reduction in false positives by 92%.
We’re with you every step of the way
Our Clinical Partnership Includes:
Pre-training and logistics including implementation planning meetings and online training
Initial onsite implementation including train-the-trainer programs, sharing best practices, demonstrations, coaching, and training certifications
Post-training resources including ongoing online training, onsite education, and retention modules
Ongoing clinical support including tracking, reporting, compliance programs, root cause analysis, and clinical reviews
We guarantee your results
With our proven technology, we guarantee you will achieve a sustained reduction in blood culture contamination of 50% or greater.
Optimize our partnership
For our most dedicated customers, our Blood Culture Integrity Partnership Program offers the greatest value and return. Ask us how.